{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T17:38:56Z","timestamp":1774460336935,"version":"3.50.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"9280","license":[{"start":{"date-parts":[[2001,8,1]],"date-time":"2001-08-01T00:00:00Z","timestamp":996624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Lancet"],"published-print":{"date-parts":[[2001,8]]},"DOI":"10.1016\/s0140-6736(01)05629-x","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T21:14:50Z","timestamp":1027631690000},"page":"489-497","source":"Crossref","is-referenced-by-count":170,"title":["Antisense therapy in oncology: new hope for an old idea?"],"prefix":"10.1016","volume":"358","author":[{"given":"Ingo","family":"Tamm","sequence":"first","affiliation":[]},{"given":"Bernd","family":"D\u00f6rken","sequence":"additional","affiliation":[]},{"given":"Gunther","family":"Hartmann","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0140-6736(01)05629-X_bib1","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/sj.leu.2401677","article-title":"Antisense therapeutics in chronic myeloid leukaemia: the promise, the progress and the problems","volume":"14","author":"Clark","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/S0140-6736(01)05629-X_bib2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1182\/blood.V92.3.712","article-title":"Nucleic acid therapeutics: state of the art and future prospects","volume":"92","author":"Gewirtz","year":"1998","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(01)05629-X_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0165-6147(00)01448-6","article-title":"Elucidating cell signaling mechanisms using antisense technology","volume":"21","author":"Koller","year":"2000","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/S0140-6736(01)05629-X_bib4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0167-4781(99)00148-7","article-title":"Molecular mechanisms of action of antisense drugs","volume":"1489","author":"Crooke","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0140-6736(01)05629-X_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0167-4781(99)00146-3","article-title":"Novel mechanisms for antisense-mediated regulation of gene expression","volume":"1489","author":"Baker","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0140-6736(01)05629-X_bib6","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2000.18.9.1812","article-title":"Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-hodgkin's lymphoma","volume":"18","author":"Waters","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib7","first-page":"3357","article-title":"Phase I study of an antisense oligonucleotide to protein kinase C-alpha (ISIS 3521\/CGP 64128A) in patients with cancer","volume":"5","author":"Yuen","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib8","first-page":"1626","article-title":"A phase I trial of c-Raf kinase antisense oligonucleotide ISIS 5132 administered as a continous intravenous infusion in patients with advanced cancer","volume":"6","author":"Cunningham","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib9","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1200\/JCO.1999.17.7.2227","article-title":"Phase I clinical\/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)","volume":"17","author":"Stevenson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib10","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1200\/JCO.1999.17.11.3586","article-title":"Phase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancer","volume":"17","author":"Nemunaitis","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib11","first-page":"1607","article-title":"Antisense approaches enter the clinic","volume":"6","author":"Khuri","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib12","doi-asserted-by":"crossref","first-page":"4370","DOI":"10.1073\/pnas.74.10.4370","article-title":"Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation","volume":"74","author":"Paterson","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib13","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1073\/pnas.75.1.280","article-title":"Inhibition of Rous sarcoma virus replication and transformation by a specific oligodeoxynucleotide","volume":"75","author":"Zamecnik","year":"1978","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.75.1.285","article-title":"Inhibition of rous sarcoma viral RNA translation by a specific oligodeoxynucleotide","volume":"75","author":"Stephenson","year":"1987","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib15","series-title":"Antisense therapy","first-page":"5","article-title":"History of antisense oligonucleotides","author":"Zamecnik","year":"1996"},{"key":"10.1016\/S0140-6736(01)05629-X_bib16","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/0092-8674(83)90401-4","article-title":"Translational control of IS10 transposition","volume":"34","author":"Simons","year":"1983","journal-title":"Cell"},{"key":"10.1016\/S0140-6736(01)05629-X_bib17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1200\/JCO.2000.18.9.1809","article-title":"Oligonucleotide therapeutics: a step forward","volume":"18","author":"Gewirtz","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/ard.1991.1.343","article-title":"In vivo modulation of N-myc expression by continous perfusion with an antisense oligonucleotide","volume":"1","author":"Whitesell","year":"1991","journal-title":"Antisense Res Dev"},{"key":"10.1016\/S0140-6736(01)05629-X_bib19","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/nm0298-232","article-title":"Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice","volume":"4","author":"Jansen","year":"1998","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(01)05629-X_bib20","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/70242","article-title":"Pleiotropic cell-division defects and apoptosis induced by interference with survivin function","volume":"1","author":"Li","year":"1999","journal-title":"Nature Cell Biology"},{"key":"10.1016\/S0140-6736(01)05629-X_bib21","first-page":"2805","article-title":"A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy","volume":"6","author":"Olie","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib22","first-page":"653","article-title":"MDM2 oncogene as a target for cancer therapy: an antisense approach","volume":"15","author":"Wang","year":"1999","journal-title":"Intl J Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib23","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/1097-0215(20000815)87:4<582::AID-IJC19>3.0.CO;2-P","article-title":"Induction of apoptosis in lung cancer cells following bcl-xL antisense treatment","volume":"87","author":"Leech","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/S0140-6736(01)05629-X_bib24","first-page":"589","article-title":"The NF-kappaB transcription factor in oncogenesis","volume":"16","author":"Sharma","year":"1996","journal-title":"Anticancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib25","doi-asserted-by":"crossref","first-page":"28259","DOI":"10.1074\/jbc.271.45.28259","article-title":"Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts","volume":"271","author":"Chen","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/S0140-6736(01)05629-X_bib26","first-page":"383","article-title":"Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in seruminduced proliferation","volume":"51","author":"Cioffi","year":"1997","journal-title":"Mol Pharmacol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib27","first-page":"1606","article-title":"Inhibition of chronic myelogenous leukaemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction","volume":"23","author":"Mahon","year":"1995","journal-title":"Exp Hematol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0076-6879(99)14115-6","article-title":"Evaluation of biological role of c-Jun N-terminal kinase using an antisense approach","volume":"314","author":"Cioffi","year":"2000","journal-title":"Methods Enzymol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib29","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1038\/sj.onc.1203538","article-title":"Treatment of prostate cancer in vitro and in vivo with 2-5A-anti-telomerase RNA component","volume":"19","author":"Kondo","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S0140-6736(01)05629-X_bib30","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1073\/pnas.85.4.1028","article-title":"Human promyelocytic leukaemia HL60 cell proliferation and c-MYC protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted agaisnt c-MYC mRNA","volume":"85","author":"Wickstrom","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib31","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/MCB.8.2.963","article-title":"An oligomer complementary to c-MYC mRNa inhibits proliferation of HL60 promyelocytic cells and induces differentiation","volume":"8","author":"Holt","year":"1988","journal-title":"Mol Cell Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib32","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1073\/pnas.86.9.3379","article-title":"An oligomer complementary to c-myb-encoded mRNA inhibits proliferation of human myeloid leukemia cell lines","volume":"86","author":"Anfossi","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib33","series-title":"Antisense therapeutics","first-page":"159","article-title":"Antisensemedited inhibition of protein synthesis","author":"Brysch","year":"1996"},{"key":"10.1016\/S0140-6736(01)05629-X_bib34","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1367-5931(99)80073-8","article-title":"Novel anticancer drug discovery","volume":"3","author":"Buolamwini","year":"1999","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib35","first-page":"9","article-title":"Antisense therapy of hematologic malignancies","volume":"36","author":"Cotter","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib36","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","article-title":"A review of issues in the pharmacokinetics and toxicology of phophorothioate antisense oligonucleotides","volume":"1489","author":"Levin","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0140-6736(01)05629-X_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1076\/ocii.7.3.189.4007","article-title":"Fomivirsen: a phosphorothioate oligonucleotide for the treatment of CMV retinitis","volume":"7","author":"de Smet","year":"1999","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/S0140-6736(01)05629-X_bib38","series-title":"Antisense therapy","first-page":"87","article-title":"Antisense tumor therapy","author":"Wickstrom","year":"1996"},{"key":"10.1016\/S0140-6736(01)05629-X_bib39","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1126\/science.281.5381.1322","article-title":"The bcl-2 protein family: arbiters of cell survival","volume":"281","author":"Adams","year":"1998","journal-title":"Science"},{"key":"10.1016\/S0140-6736(01)05629-X_bib40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00001622-199511000-00012","article-title":"Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance","volume":"7","author":"Reed","year":"1995","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00000372-199502000-00002","article-title":"Bcl-2 expression in cutaneous malignant melanoma and benign melanocytic nevi","volume":"17","author":"Cerroni","year":"1995","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib42","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S0140-6736(00)03207-4","article-title":"Chemosensitization of malignant melanoma by BCL2 antisense therapy","volume":"356","author":"Jansen","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(01)05629-X_bib43","first-page":"178a","article-title":"A phase I study of bcl-2 antisense G3139 (GENTA) and weekly docetaxel in patients with advanced breast cancer and other solid tumors","volume":"19","author":"Chen","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl","key":"10.1016\/S0140-6736(01)05629-X_bib44","first-page":"4571s","article-title":"A phase I, pharmacokinetic and biologic correlative study of G3139 (Bcl-2 antisense oligonucleotide) and Docetaxel in patients with hormone-refractory prostate cancer (HRPC)","volume":"6","author":"Tolcher","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib45","first-page":"330a","article-title":"A phase I trial of an antisense oligonucleotide to bcl-2 (G3139, Genta) and mitoxantrone in patients with metastatic hormone refractory prostate cancer (HRPC)","volume":"19","author":"Chi","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib46","first-page":"459a","article-title":"A phase I\/II trial of ISIS 3521, an antisense inhibitor of protein kinase C alpha, combined with carboplatin and paclitaxel in patients with non-small cell lung cancer","volume":"19","author":"Yuen","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"suppl","key":"10.1016\/S0140-6736(01)05629-X_bib47","first-page":"4572s","article-title":"Phase I\/II trial of ISIS 3521, an antisense inhibitor of PKC, with carboplatin and paclitaxel in nonsmall cell lung cancer","volume":"6","author":"Yuen","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib48","first-page":"167a","article-title":"Efficacy, toxicity, and pharmacology of an antisense oligonucleotide directed against protein kinase C-alpha (ISIS 3521) delivered as a 21 day continous intravenous infusion in patients with recurrent high grade astrocytomas (HGA)","volume":"19","author":"Alavi","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib49","first-page":"4682","article-title":"Ras oncogenes in human cancer: a review","volume":"49","author":"Bos","year":"1989","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev.cb.07.110191.003125","article-title":"Regulators and effectors of ras protein","volume":"7","author":"Bollag","year":"1991","journal-title":"Annu Rev Cell Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib51","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1200\/JCO.1999.17.4.1095","article-title":"Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors","volume":"17","author":"Eckhardt","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib52","first-page":"3977","article-title":"c-raf-1 depletion and tumor responses in patients treated with the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)","volume":"5","author":"O'Dwyer","year":"1999","journal-title":"Clin Canc Res"},{"issue":"suppl","key":"10.1016\/S0140-6736(01)05629-X_bib53","first-page":"4572s","article-title":"Phase II study of c-raf kinase antisense oligonucleotide ISIS 5132 in patients with recurrent ovarian cancer","volume":"6","author":"Oza","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib54","first-page":"320a","article-title":"A phase II trial of ISIS 2503, an antisense inhibitor of H-ras, as first line therapy for advanced colorectal carcinoma","volume":"19","author":"Saleh","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib55","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0167-4781(99)00142-6","article-title":"Oligonucleotide therapeutics for hematologic disorders","volume":"1489","author":"Agarwal","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/S0140-6736(01)05629-X_bib56","first-page":"250a","article-title":"A phase I and pharmacokinetik (PK) study of the human DNA methyltransferase (Metase) antisense oligodeoxynucleotide MG98 given as a 21-day continous infusion every 4 weeks","volume":"19","author":"Siu","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib57","doi-asserted-by":"crossref","first-page":"13989","DOI":"10.1073\/pnas.96.24.13989","article-title":"Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration","volume":"96","author":"Wang","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib58","doi-asserted-by":"crossref","first-page":"944","DOI":"10.4049\/jimmunol.164.2.944","article-title":"Mechanism and function of a newly identified CpG DNA motif in human primary B cells","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib59","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/BF03401902","article-title":"Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phophorothioate modifications and reversal by heparin","volume":"2","author":"Hartmann","year":"1996","journal-title":"Mol Med"},{"key":"10.1016\/S0140-6736(01)05629-X_bib60","doi-asserted-by":"crossref","first-page":"9305","DOI":"10.1073\/pnas.96.16.9305","article-title":"CpG DNA as a signal for growth, activation and maturation of human dendritic cells","volume":"96","author":"Hartmann","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib61","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.4049\/jimmunol.164.3.1617","article-title":"Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo","volume":"164","author":"Hartmann","year":"2000","journal-title":"J Immunol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib62","first-page":"1","article-title":"Mechanism of action of CpG DNA","volume":"247","author":"Krieg","year":"2000","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(01)05629-X_bib64","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0167-5699(00)01719-9","article-title":"Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA","volume":"21","author":"Krieg","year":"2000","journal-title":"Immunol Today"},{"key":"10.1016\/S0140-6736(01)05629-X_bib65","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/oli.1.1996.6.63","article-title":"Bias in nucleotide composition of antisense oligonucleotides","volume":"6","author":"Smetsers","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S0140-6736(01)05629-X_bib66","first-page":"157","article-title":"CpG DNA in cancer immunotherapy","volume":"247","author":"Weiner","year":"2000","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib67","first-page":"2492","article-title":"Eradication of human non Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low dose cyclophosphamide","volume":"6","author":"Klasa","year":"2000","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1189\/jlb.69.1.81","article-title":"CpG DNA increases immunogenicity and target-antigen expression of primary B cell non-Hodgkin lymphoma cells","volume":"69","author":"Jahrsd\u00f6rfer","year":"2001","journal-title":"J Leuk Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib69","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1101\/gad.13.3.239","article-title":"IAP family proteins: suppressors of apoptosis","volume":"13","author":"Deveraux","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/S0140-6736(01)05629-X_bib70","first-page":"1796","article-title":"Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias","volume":"6","author":"Tamm","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/40901","article-title":"X-linked IAP is a direct inhibitor of cell death proteases","volume":"388","author":"Deveraux","year":"1997","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(01)05629-X_bib72","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.1074\/jbc.273.14.7787","article-title":"A single BIR domain of XIAP sufficient for inhibiting caspases","volume":"273","author":"Takahashi","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/S0140-6736(01)05629-X_bib73","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V93.11.3601","article-title":"The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18)(q21;q21) associated with mucosa-associated lymphoid tissue lymphomas","volume":"93","author":"Dierlamm","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(01)05629-X_bib74","first-page":"384a","article-title":"Fusion between the apoptosis inhibitor gene API2 and a novel 18q gene MLT, rearranged in the t(11;18)(q21;q21), marks half of the gastro-intestinal MALT-type lymphomas without large cell proliferation","volume":"94","author":"Baens","year":"1999","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(01)05629-X_bib75","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nm0897-917","article-title":"A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma","volume":"3","author":"Ambrosini","year":"1997","journal-title":"Nat Med"},{"key":"10.1016\/S0140-6736(01)05629-X_bib76","first-page":"5315","article-title":"IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs","volume":"58","author":"Tamm","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib77","first-page":"1808","article-title":"Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas","volume":"58","author":"Lu","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib78","first-page":"5071","article-title":"Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer","volume":"58","author":"Kawasaki","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib79","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1200\/JCO.1999.17.7.2100","article-title":"A novel anti-apoptosis gene: Reexpression of survivin messenger RNA as a prognosis marker in nonsmall-cell lung cancers","volume":"17","author":"Monzo","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib80","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1136\/gut.46.5.645","article-title":"Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma","volume":"46","author":"Sarela","year":"2000","journal-title":"Gut"},{"key":"10.1016\/S0140-6736(01)05629-X_bib81","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/sj.onc.1203358","article-title":"High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma","volume":"19","author":"Islam","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S0140-6736(01)05629-X_bib82","first-page":"127","article-title":"Expression of survivin and its relationship to loss of apoptosis in breast carcinomas","volume":"6","author":"Tanaka","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib83","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM199908053410614","article-title":"Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer","volume":"341","author":"Swana","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/S0140-6736(01)05629-X_bib84","doi-asserted-by":"crossref","first-page":"3238","DOI":"10.1074\/jbc.M003670200","article-title":"Livin, a novel inhibitor-of-apoptosis (IAP) family member","volume":"276","author":"Kasof","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/S0140-6736(01)05629-X_bib85","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S0140-6736(05)70294-4","article-title":"Anti-apoptosis gene, survivin, and prognosis of neuroblastoma","volume":"351","author":"Adida","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/S0140-6736(01)05629-X_bib86","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/25141","article-title":"Control of apoptosis and mitotic spindle checkpoint by survivin","volume":"396","author":"Li","year":"1998","journal-title":"Nature"},{"key":"10.1016\/S0140-6736(01)05629-X_bib87","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1038\/sj.onc.1203665","article-title":"Survivin initiates cell cycle entry by the competitive interaction with Cdk-4\/p16INK4a and Cdk2\/Cyclin E complex activation","volume":"19","author":"Suzuki","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/S0140-6736(01)05629-X_bib88","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/70227","article-title":"Survivin' cell-separation anxiety","volume":"1","author":"Reed","year":"1999","journal-title":"Nat Cell Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib89","first-page":"2805","article-title":"A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy","volume":"6","author":"Olie","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib90","first-page":"462a","article-title":"Down-regulation of survivin by antisense oligonucleotides in plasmocytoma cells leads to increased apoptosis and sensitivity to chemotherapeutic drugs","volume":"96","author":"Tamm","year":"2000","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(01)05629-X_bib91","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1006\/excr.1999.4455","article-title":"Escaping cell death: survival proteins in cancer","volume":"248","author":"Jaattela","year":"1999","journal-title":"Exp Cell Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib92","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1073\/pnas.88.5.1681","article-title":"Thermal response of rat fibroblasts stably transfected with the human 70-kDa heat shock protein-encoding gene","volume":"88","author":"Li","year":"1991","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/S0140-6736(01)05629-X_bib93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1083\/jcb.109.1.7","article-title":"Heat shock resistance conferred by expression of the human HSP27 gene in rodent cells","volume":"109","author":"Landry","year":"1989","journal-title":"J Cell Biol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib94","first-page":"1603","article-title":"Expression of the heat shock protein HSP27 in human ovarian cancer","volume":"1","author":"Langdon","year":"1995","journal-title":"Clin Canc Res"},{"key":"10.1016\/S0140-6736(01)05629-X_bib95","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2336::AID-CNCR7>3.0.CO;2-J","article-title":"Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma: relationship with poor prognosis","volume":"79","author":"Uozaki","year":"1997","journal-title":"Cancer"},{"issue":"suppl","key":"10.1016\/S0140-6736(01)05629-X_bib96","first-page":"59","article-title":"The role of chromosome translocations in leukemogenesis","volume":"36","author":"Rowley","year":"1999","journal-title":"Semin Hematol"},{"key":"10.1016\/S0140-6736(01)05629-X_bib97","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised european-american classification of lymphoid neoplasms: a proposal from the international study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/S0140-6736(01)05629-X_bib98","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/oli.1.1996.6.3","article-title":"Telomerase as a potential molecular target to study G-quartet phosphorothioates","volume":"6","author":"Sharma","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/S0140-6736(01)05629-X_bib99","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0167-4781(99)00150-5","article-title":"Morpholino antisense oligomers: the case for an RNase H-independent structural type","volume":"1489","author":"Summerton","year":"1999","journal-title":"Biochim Biophys Acta"}],"container-title":["The Lancet"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067360105629X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014067360105629X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T19:36:10Z","timestamp":1681414570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014067360105629X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,8]]},"references-count":99,"journal-issue":{"issue":"9280","published-print":{"date-parts":[[2001,8]]}},"alternative-id":["S014067360105629X"],"URL":"https:\/\/doi.org\/10.1016\/s0140-6736(01)05629-x","relation":{},"ISSN":["0140-6736"],"issn-type":[{"value":"0140-6736","type":"print"}],"subject":[],"published":{"date-parts":[[2001,8]]}}}